



King's Research Portal

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Parente-Pereira, A. C., Krishnamurthy, P., Whilding, L., Ioannou, K., Ciprut, S., Potter, V., Mufti, G., Barber, L., Farzaneh, F., & Maher, J. (2020). Efficient Ex Vivo Expansion of $\gamma\delta$ T-Cells from AML Patients Requires Elimination of Circulating Leukemic Blasts. *Advances in Leukemia Research and Treatment*, 2(1), 28-33.

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Brief Communication

DOI: 10.36959/486/327

Efficient *Ex Vivo* Expansion of $\gamma\delta$ T-Cells from AML Patients Requires Elimination of Circulating Leukemic Blasts

Ana C Parente-Pereira¹, Pramila Krishnamurthy², Lynsey M Whilding¹, Kyriaki Ioannou³, Sara Ciprut¹, Victoria Potter², Ghulam J Mufti^{2,3}, Linda Barber³, Farzin Farzaneh³ and John Maher^{1,4,5,6*}



¹King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK

²Department of Haematological Medicine, King's College Hospital, Denmark Hill, London SE5 9RS, UK

³King's College London, School of Cancer and Pharmaceutical Sciences, The Rayne Institute, London SE5 9NU, UK

⁴Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex, BN21 2UD, UK

⁵Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK

⁶Leucid Bio Ltd., Guy's Hospital, Great Maze Pond, London SE1 9RT, UK

Abstract

$\gamma\delta$ T-cells play an important role in immune surveillance of acute myeloid leukemia (AML). The main circulating subtype expresses a V γ 9V δ 2 T-cell receptor and may be expanded *ex vivo* following aminobisphosphonate activation. While such protocols operate robustly in healthy donors, they are often inefficient using blood samples from patients with advanced malignancy. In keeping with this, we found that when leukemic blasts were present in peripheral blood samples, culture of $\gamma\delta$ T-cells from patients with AML was unsuccessful. By contrast, expansion proved much more effective after chemotherapy-mediated clearance of circulating blasts, yielding similar $\gamma\delta$ T-cell numbers to healthy donors. This principle was confirmed using serial samples obtained from the same patients. Importantly, expanded $\gamma\delta$ T-cells were functional, indicated by bisphosphonate-potentiated anti-leukemic activity and cytokine release *in vitro*. These preliminary findings suggest a therapeutic potential for $\gamma\delta$ T-cells, given that they can be readily expanded from AML patients in therapy-induced remission.

Keywords

Leukemia, Adoptive immunotherapy, $\gamma\delta$ t-cell, Zoledronic acid

Introduction

$\gamma\delta$ T-cells account for up to 3% of peripheral blood mononuclear cells (PBMC). In man, most express the V γ 9V δ 2 receptor, enabling their MHC-independent activation by phosphoantigen (PAG) intermediates of the mevalonate pathway [1]. Dysregulation of mevalonate pathway metabolism is prevalent in AML [2], accounting for the frequent sensitivity of leukemic cells to statins [3] or aminobisphosphonates (e.g. alendronic and zoledronic acid) [4].

Several clinical observations demonstrate a role for $\gamma\delta$ T-cells in immune surveillance of AML [5]. First, prolonged survival of AML patients after allogeneic hematopoietic stem cell transplantation (HSCT) correlates with enhanced $\gamma\delta$ T-cell recovery. Second, these cells may be expanded *ex vivo* fol-

lowing $\alpha\beta$ T-cell-depleted haploidentical HSCT and exhibit potent cytolytic activity against primary AML cells. Third, infusion of haploidentical $\gamma\delta$ T-cells followed by administration of zoledronic acid and IL-2 has induced complete remission

***Corresponding author:** Department of Research Oncology, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK, Tel: 0044-207-188-1468; Fax: 0044-207-188-0919

Accepted: December 26, 2020

Published online: December 28, 2020

Citation: Parente-Pereira AC, Krishnamurthy P, Whilding LM, et al. (2020) Efficient *Ex Vivo* Expansion of $\gamma\delta$ T-Cells from AML Patients Requires Elimination of Circulating Leukemic Blasts. *Advances Leuk Res Treat* 2(1):28-33

Copyright: © 2020 Parente-Pereira AC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Table 1: Clinical information pertaining to samples tested.

Patient Number	Clinical information	Age	Prior treatment	Interval post CTX (days)	Circulating blasts
001 - sample 1	M1 (FLT3 ITD-)	42	Nil	No CTX	Yes
001 - sample 2			DA × 1	17	No
001 - sample 3			DA × 1 FLAG IDA × 2	42	No*
002 - sample 1	M1 (FLT3 ITD+ NPM+)	19	Nil	No CTX	Yes
002 - sample 2			DA × 1	21	No
003 - sample 1	Transformed from JAK2 mutant myeloproliferative disorder	N/A	FLA × 1	0	No
003 - sample 2			FLA × 1	26	Yes
004 - sample 1	M4 (Inv16)	23	HU	0	No
004 - sample 2			HU + DA × 1	26	No
005 - sample 1	Transformed from refractory anemia with excess blasts with Inv (3)(q21q26)	N/A	DA	46	No
005 - sample 2			DA × 2	15	No
006	M1 FLT3 ITD+	41	DA × 1	28	No
007 - sample 1	M1 FLT3 ITD+	56	DA × 1	25	No
007 - sample 2			DA × 2	28	No
008	M4 t(6;11)(q27;q23)	22	DA × 1	28	No
009	Transformed from JAK2 mutant myeloproliferative disorder; trisomy 8	57	Nil	No CTX	Yes
010	N/A	N/A	Nil	No CTX	Yes

CTX - chemotherapy; DA - daunorubicin + cytarabine; FLA - fludarabine + cytarabine; FLAG-IDA - fludarabine, cytarabine, G-CSF, idarubicin; HU - hydroxyurea; N/A - not available;

*Absolute lymphocyte count $0.2 \times 10^9/L$ with no CD3⁺ cells detectable. Consequently, no expansion of $\gamma\delta$ T-cells was observed from this sample.

in patients with advanced hematologic malignancy, including AML. Fourth, *in vivo* activation of these cells with zoledronic acid and IL-2 has achieved an efficacy signal in AML patients.

These findings provide a rationale to develop $\gamma\delta$ T-cell-based immunotherapeutic strategies for AML. In AML patients, circulating $\gamma\delta$ T-cells [6,7] which may be expanded *ex vivo* using the synthetic PAG, Phosphostim. Since Phosphostim is no longer undergoing clinical development, we evaluated an alternative system comprising zoledronic acid, IL-2 and IL-15 [8]. We have previously shown that this cocktail can expand $\gamma\delta$ T-cells from patients with ovarian cancer [8] and hypothesized that a similar approach could be applied in AML patients.

Methods

Processing of peripheral blood samples

Seventeen blood samples (30 mL each) derived from 10 AML patients (clinical data - Table 1) were provided by the King's College London Haemato-Oncology Tissue Bank (Human Tissue Authority license 12223; National Research Ethics reference 08/H0906/94). All patient-derived peripheral blood samples were independently analyzed for the presence of circulating AML blasts by morphology alone, or accompa-

nied by flow cytometry at the time of banking. Blood samples were also obtained from healthy donors under approval of the South East London Research Ethics Committee 1 (09/H0804/92).

Culture of primary human $\gamma\delta$ T-cells

Ficoll-separated PBMC were cultured at 3×10^6 cells/ml in RPMI 1640 (Lonza, Basel, Switzerland), 10% human AB serum (Sigma, Poole, UK), GlutaMax (Life Technologies, Paisley, UK) and antibiotic-antimycotic solution (Life Technologies). On day 1, zoledronic acid (1 $\mu\text{g/ml}$; Zometa, Novartis, Frimley/Camberley, UK), IL-2 (100 U/ml; Proleukin, Novartis) and IL-15 (10 ng/ml; Gentaur, Kampenhout, Belgium) were added. Additional medium and cytokines were added every 2-3 day for 15 days. Numbers of $\gamma\delta$ T-cells were determined manually as total cell number multiplied by percentage $\gamma\delta$ T-cells in the PBMC gate/100.

Flow cytometry

Flow cytometric analysis was undertaken on freshly isolated PBMC and *ex vivo* expanded $\gamma\delta$ T-cell cultures as described [8], using antibodies listed in Supplementary Table 1. Analysis was performed using a FACScalibur cytometer with Cellquest Pro software. Representative forward scatter versus side

scatter gating strategies on freshly isolated PBMC are shown (Supplementary Figure 1).

Cytotoxicity assays

PKH-labeled KG-1 leukemic cells were incubated \pm zoledronic acid (5 $\mu\text{g/ml}$) or alendronic acid (20 $\mu\text{g/ml}$) overnight before co-culture with $\gamma\delta$ T-cells at the indicated effector:target ratio for 4 hours. Apoptotic cells were detected after Annexin V staining by flow cytometry (Supplementary Figure 2) [8].

Enzyme-linked immunosorbent assay

Supernatants were analyzed using a human IFN- γ enzyme-linked immunosorbent assay (ELISA; Ready-set-go kit

(eBiosciences, Hatfield, UK)) as described by the manufacturers.

Statistical analysis

Statistical analysis was performed using One-way ANOVA for analysis of groups of 3 or more datasets. Alternatively, an unpaired two-tailed Student's *t* test or Mann-Whitney test was used to compare two groups, where data passed or failed normality testing respectively. All statistical analyses were performed using GraphPad Prism version 5.0, 6.0 or 7.0 (GraphPad software, San Diego, CA, USA).

Results and Discussion

Expansion of $\gamma\delta$ T-cells from AML patients





Figure 1: *Ex vivo* expansion of $\gamma\delta$ T-cells from AML patients with circulating blast cells is inefficient. (A) PBMC were separated from two patients with newly diagnosed AML (AML001 - M1 subtype without FLT3 internal tandem duplication (ITD); AML002 - M1 with FLT3 ITD and *NPM1* mutation) in whom circulating blast cells were present. Samples were stained with a pan- $\gamma\delta$ TCR antibody (open green histogram) and analyzed by flow cytometry, making comparison with an isotype control antibody (filled purple histogram) (day 1). Cultures were then stimulated with ZA followed by IL-2/IL-15 for 15 days prior to re-analysis using similar methodology; (B) Pooled data from 5 AML patients in whom circulating leukemic blasts were present at the time of PBMC collection. In each case, $\gamma\delta$ T-cell number was determined manually before (day 1-30mL blood sample) or after culture of derived PBMC for 15 days in zoledronic acid + IL-2/IL-15; (C) Following one cycle of daunorubicin plus cytarabine (DA) induction chemotherapy, PBMC from patients AML001 and AML002 were re-analyzed for $\gamma\delta$ T-cells by flow cytometry, both before and after culture in zoledronic acid + IL-2/IL-15; (D) Following 1 cycle of fludarabine plus cytarabine (FLA) chemotherapy, PBMC were separated from AML003 (AML derived from JAK2 mutant myeloproliferative disorder) and were analyzed by flow cytometry before and after culture in zoledronic acid + IL-2/IL-15, as described above. Twenty nine days later, relapse occurred accompanied by circulating blasts and a second sample was analyzed similarly.



We explored the feasibility of zoledronic acid-mediated $\gamma\delta$ T-cell expansion from patients with AML. However, only a relatively small percentage of $\gamma\delta$ T-cells could be identified in ficoll-separated PBMC derived from newly diagnosed AML patients (representative examples - Figure 1A). Furthermore, zoledronic acid-mediated expansion of these cells was either inefficient or unsuccessful in each of five consecutive attempts (Figure 1B).

Patients with AML who achieve minimal residual disease status following chemotherapy are reported to have increased circulating $\gamma\delta$ T-cell numbers. By contrast, these cells are substantially reduced in patients with high disease burden [6]. Consequently, we hypothesized that disease status might be responsible for poor zoledronic acid-mediated $\gamma\delta$ T-cell

expansion. To test this, we obtained further blood samples from two of the previously described AML patients (AML001 and AML002), following induction chemotherapy with a single cycle of daunorubicin and cytarabine (DA) chemotherapy. In both cases, a discrete population of $\gamma\delta$ T-cells was now evident in isolated PBMC (Figure 1C). Moreover, $\gamma\delta$ T-cells expanded efficiently following zoledronic acid-mediated activation (Figure 1C), contrasting with the failure of expansion observed prior to chemotherapy. Conversely, sequential samples were also obtained from a third patient (AML003), immediately following FLA chemotherapy (fludarabine/cytarabine), when circulating blasts were undetectable, or following subsequent disease relapse. In this case, a clearly distinct $\gamma\delta$ T-cell population was only detected in the leukemia-free sam-

ple and these cells alone were amenable to efficient expansion by ZA (Figure 1D).

Characterization of circulating and *ex vivo* expanded $\gamma\delta$ T-cells from AML patients

These preliminary findings suggested that it would be more profitable to expand circulating $\gamma\delta$ T-cells from peripheral blood in which circulating leukemic blasts were absent following chemotherapy. In such AML patients, $\gamma\delta$ T-cells accounted for $1.55 \pm 3.13\%$ of PBMC ($19,388 \pm 12,302$ $\gamma\delta$ cells/ml blood; mean \pm SD, $n = 11$), which was not significantly different to healthy donors ($19,916 \pm 29,887$, mean \pm SD, $n = 21$) [8]. In all cases but one, these $\gamma\delta$ T-cells were amenable to zoledronic acid-mediated enrichment, unlike those from patients with circulating leukemic cells (Figure 2A). In the single case that expansion failed, there were no CD3⁺ T-cells detectable (Table 1).

Next, we analyzed the expansion and immunophenotype of zoledronic acid-expanded $\gamma\delta$ T-cells following chemotherapy-mediated clearance of circulating blasts. We observed that these cells expanded by an average of 229-fold (Figure 2B), which is similar to healthy donors [8]. Expanded cells exhibited high levels of CD27, CD62L and CCR7 and lower expression of CD70 (Supplementary Figure 3 and Supplementary Figure 4), consistent with the presence of central memory cells [9,10].

Expression of NKG2D also plays an important role in the ability of $\gamma\delta$ T-cells to recognize stress ligands on AML blasts [11], although recent data has raised doubts about the expression of such ligands on the stem cell compartment [12]. Cells expanded from AML patients post-chemotherapy expressed comparable high levels of NKG2D to cells derived from healthy donors (Supplementary Figures 3 and Supplementary Figure 4). Furthermore, these cells consistently exhibited anti-leukemic cytotoxic activity in a manner that was potentiated by bisphosphonate sensitization (Figure 2C and Supplementary Figure 1) and accompanied by IFN- γ release (Figure 2D).

Conclusions

The major finding of this short communication is that functional $\gamma\delta$ T-cells can only be expanded efficiently from AML patients after chemotherapy-mediated clearance of circulating leukemic cells. Mechanistically, this may reflect the uncoupling of the multiple immunosuppressive mechanisms that are found in newly diagnosed or relapsed AML. Leukemic blasts have been compared to myeloid-derived suppressor cells. In active disease, there is also an increase in regulatory T-cells, immunosuppressive exosomes and inhibitory molecules such as CD200, PD-L1 and indoleamine dioxygenase [13-20]. Future studies should undertake mixing/depletion experiments with AML cells, analysing effects on $\gamma\delta$ T-cell numbers, phenotype and exhaustion markers. Furthermore, in planning for immunotherapy of AML with autologous *ex vivo* expanded $\gamma\delta$ T-cells, our data suggest that harvest of starting material should be scheduled when disease is in remission. This is logical since disease burden and circulating blasts are minimal at this time while $\gamma\delta$ T-cells are most amenable to

expansion, while retaining anti-leukemic activity.

Funding

This work was supported by Bloodwise [programme 13007]; the Experimental Cancer Medicine Centre at King's College London and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' National Health Service (NHS) Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Declaration of Competing Interests

J.M. is a founding scientist of Leucid Bio. Other authors declare no competing financial interests.

Acknowledgements

We thank members of the King's College London Haemato-Oncology Tissue Bank for provision of blood samples.

References

1. HJ Gober, M Kistowska, L Angman, et al. (2003) Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. *J Exp Med* 197: 163-168.
2. A Pandya, PJ Mullen, M Kalkat, et al. (2014) Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. *Cancer Res* 74: 4772-4782.
3. HY Li, FR Appelbaum, CL Willman, et al. (2003) Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. *Blood* 101: 3628-3634.
4. M Fiegl, M Juergens, W Hiddemann, et al. (2007) Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia. *Leuk Res* 31: 531-539.
5. L Halim, AC Parente-Pereira, J Maher (2017) Prospects for immunotherapy of acute myeloid leukemia using gammadelta T cells. *Immunotherapy* 9: 111-114.
6. JM Aswald, XH Wang, S Aswald, et al. (2006) Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?. *Cytometry B Clin Cytom* 70: 379-390.
7. J Gertner-Dardenne, R Castellano, E Mamessier, et al. (2012) Human Vgamma9Vdelta2 T cells specifically recognize and kill acute myeloid leukemic blasts. *J Immunol* 188: 4701-4708.
8. AC Parente-Pereira, H Shmeeda, LM Whilding, et al. (2014) Adoptive immunotherapy of epithelial ovarian cancer with Vgamma9Vdelta2 T cells, potentiated by liposomal alendronic acid. *J Immunol* 193: 5557-5566.
9. M Eberl, R Engel, E Beck, et al. (2002) Differentiation of human gamma-delta T cells towards distinct memory phenotypes. *Cell Immunol* 218: 1-6.
10. F Dieli, F Poccia, M Lipp, et al. (2003) Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. *J Exp Med* 198: 391-397.
11. S Gundermann, E Klinker, B Kimmel, et al. (2014) A comprehensive analysis of primary acute myeloid leukemia identifies bio-

- markers predicting susceptibility to human allogeneic Vgamma-9Vdelta2 T cells. *J Immunother* 37: 321-330.
12. AM Paczulla, K Rothfelder, S Raffel, et al. (2019) Absence of NK-G2D ligands defines leukaemia stem cells and mediates their immune evasion. *Nature* 572: 254-259.
 13. Q Zhou, ME Munger, SL Highfill, et al. (2010) Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. *Blood* 116: 2484-2493.
 14. T Tian, S Yu, L Liu, et al. (2015) The Profile of T Helper Subsets in Bone Marrow Microenvironment Is Distinct for Different Stages of Acute Myeloid Leukemia Patients and Chemotherapy Partly Ameliorates These Variations. *PLoS One* 10: e0131761.
 15. SJ Coles, MN Gilmour, R Reid, et al. (2015) The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. *Leukemia* 29: 1952-1954.
 16. MJ Szczepanski, M Szajnik, M Czystowska, et al. (2009) Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. *Clin Cancer Res* 15: 3325-3332.
 17. A Curti, S Trabanelli, C Onofri, et al. (2010) Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. *Haematologica* 95: 2022-2030.
 18. T Hoeres, E Holzmann, M Smetak, et al. (2019) PD-1 signaling modulates interferon-gamma production by Gamma Delta (gammadelta) T-Cells in response to leukemia. *Oncoimmunology* 8: 1550618.
 19. CS Hong, P Sharma, SS Yerneni, et al. (2017) Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia. *Sci Rep* 7: 14684.
 20. AJ Barrett (2020) Acute myeloid leukaemia and the immune system: implications for immunotherapy. *Br J Haematol* 188: 147-158.

DOI: 10.36959/486/327

Copyright: © 2020 Parente-Pereira AC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

